tetano
Editor, Senior Moderator
Sci Rep
. 2024 May 6;14(1):10324.
doi: 10.1038/s41598-024-61133-z. Multi-cohort study on cytokine and chemokine profiles in the progression of COVID-19
Chaolin Huang[SUP] #[/SUP][SUP] 1 2 [/SUP], Xujuan Hu[SUP] #[/SUP][SUP] 1 [/SUP], Delong Wang[SUP] #[/SUP][SUP] 1 3 [/SUP], Rui Gong[SUP] #[/SUP][SUP] 1 3 [/SUP], Qiongya Wang[SUP] #[/SUP][SUP] 1 [/SUP], Fuli Ren[SUP] 1 2 [/SUP], Yuanjun Wu[SUP] 1 [/SUP], Juan Chen[SUP] 1 [/SUP], Xianglian Xiong[SUP] 1 [/SUP], Huadong Li[SUP] 1 [/SUP], Qian Wang[SUP] 1 [/SUP], Gangyu Long[SUP] 1 [/SUP], Dingyu Zhang[SUP] 4 5 [/SUP], Yang Han[SUP] 6 7 [/SUP]
Affiliations
Various substances in the blood plasma serve as prognostic indicators of the progression of COVID-19. Consequently, multi-omics studies, such as proteomic and metabolomics, are ongoing to identify accurate biomarkers. Cytokines and chemokines, which are crucial components of immune and inflammatory responses, play pivotal roles in the transition from mild to severe illness. To determine the relationship between plasma cytokines and the progression of COVID-19, we used four study cohorts to perform a systematic study of cytokine levels in patients with different disease stages. We observed differential cytokine expression between patients with persistent-mild disease and patients with mild-to-severe transformation. For instance, IL-4 and IL-17 levels significantly increased in patients with mild-to-severe transformation, indicating differences within the mild disease group. Subsequently, we analysed the changes in cytokine and chemokine expression in the plasma of patients undergoing two opposing processes: the transition from mild to severe illness and the transition from severe to mild illness. We identified several factors, such as reduced expression of IL-16 and IL-18 during the severe phase of the disease and up-regulated expression of IL-10, IP-10, and SCGF-β during the same period, indicative of the deterioration or improvement of patients' conditions. These factors obtained from fine-tuned research cohorts could provide auxiliary indications for changes in the condition of COVID-19 patients.
. 2024 May 6;14(1):10324.
doi: 10.1038/s41598-024-61133-z. Multi-cohort study on cytokine and chemokine profiles in the progression of COVID-19
Chaolin Huang[SUP] #[/SUP][SUP] 1 2 [/SUP], Xujuan Hu[SUP] #[/SUP][SUP] 1 [/SUP], Delong Wang[SUP] #[/SUP][SUP] 1 3 [/SUP], Rui Gong[SUP] #[/SUP][SUP] 1 3 [/SUP], Qiongya Wang[SUP] #[/SUP][SUP] 1 [/SUP], Fuli Ren[SUP] 1 2 [/SUP], Yuanjun Wu[SUP] 1 [/SUP], Juan Chen[SUP] 1 [/SUP], Xianglian Xiong[SUP] 1 [/SUP], Huadong Li[SUP] 1 [/SUP], Qian Wang[SUP] 1 [/SUP], Gangyu Long[SUP] 1 [/SUP], Dingyu Zhang[SUP] 4 5 [/SUP], Yang Han[SUP] 6 7 [/SUP]
Affiliations
- PMID: 38710800
- DOI: 10.1038/s41598-024-61133-z
Various substances in the blood plasma serve as prognostic indicators of the progression of COVID-19. Consequently, multi-omics studies, such as proteomic and metabolomics, are ongoing to identify accurate biomarkers. Cytokines and chemokines, which are crucial components of immune and inflammatory responses, play pivotal roles in the transition from mild to severe illness. To determine the relationship between plasma cytokines and the progression of COVID-19, we used four study cohorts to perform a systematic study of cytokine levels in patients with different disease stages. We observed differential cytokine expression between patients with persistent-mild disease and patients with mild-to-severe transformation. For instance, IL-4 and IL-17 levels significantly increased in patients with mild-to-severe transformation, indicating differences within the mild disease group. Subsequently, we analysed the changes in cytokine and chemokine expression in the plasma of patients undergoing two opposing processes: the transition from mild to severe illness and the transition from severe to mild illness. We identified several factors, such as reduced expression of IL-16 and IL-18 during the severe phase of the disease and up-regulated expression of IL-10, IP-10, and SCGF-β during the same period, indicative of the deterioration or improvement of patients' conditions. These factors obtained from fine-tuned research cohorts could provide auxiliary indications for changes in the condition of COVID-19 patients.